Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO?

Combining an emerging way of attacking cancer, an early-stage drug licensed from giant Novartis AG and its principals' deep roots in Bay Area biotech, a Peninsula company is seeking $70 million through an initial public offering.